Posted by Michael Wonder on 07 Apr 2022
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
7 April 2022 - NICE has today issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
The draft guidance, which is available for public consultation until 29 April 2022, says that, although sacituzumab govitecan increases how long people have before their disease gets worse and how long they live compared with chemotherapy, at its current price it is too expensive to be considered a cost-effective use of NHS resources.
